Company Cash Volume: Rallybio Corp (RLYB)

Graphic logo of Rallybio Corporation (RLYB)

Rallybio Corporation (RLYB) possesses immense growth potential due to the specific nature of the biotech sector. The company's free cash flow confirms this trajectory, where the value of 0.09 serves as a baseline liquidity indicator. However, high testing costs in the absence of sales and the risk of trial failure are creating pressure. Access to monopoly pricing will only open following the approval of orphan drugs.

RLYB - rallybio.com Company Liquid Assets over the range 07/04/2022 - 11/21/2026

Financial and market metric breakdowns for Rallybio Corporation (RLYB)

- current price and projected stock value:
- company stock exchange capitalization indicators:
Fundamental company analysis:RLYB Rallybio
Product sample of Rallybio Corp.

An analysis of Rallybio Corporation (RLYB) cash reserves allows for an assessment of its ability to fund costly clinical trials and support the development of drugs for treating rare fetal pathologies. This metric measures liquidity for covering short-term obligations, where excess reserves guarantee business survival in the absence of revenue, yet may indicate low capital efficiency within the long-term consensus.

Competitors of Rallybio Corporation (RLYB)

Company Cash Funds Haleon (HLN)|Company Cash Volume Kenvue Inc. (KVUE)|Company Cash Volume VRNA (veronapharma.com)|Company Cash Balance MENS|LGND: Company Cash on Hand|Company Cash Balance AMRX (Amneal Corp)|PRGO (Perrigo Company plc) - Company Cash on Hand|Alvotech - Company Cash Balance|Company Cash on Hand LQDA|Galapagos Genomics (GLPG) - Company Liquid Assets|Company Cash Volume ANIP|Company Cash on Hand Afrezza MNKD|Company Cash Funds Amphastar AMPH|Company Liquid Assets Pacira BioSciences (PCRX)|ARS Corp - Company Cash Volume|TBPH: Company Cash Funds|AQST: Company Cash Volume|SCPH - Company Liquid Assets|TECX (Tectonic) - Company Cash Volume|Company Cash Reserve Tonix Pharmaceuticals Holding Corp. TNXP|Company Cash Funds SXT Pharmaceuticals (SXTC)|Company Cash Volume Eupraxia Pharmaceuticals Inc. (EPRX)|Company Cash Funds BioHarvest Sciences BHST|EXOZ (Invizyne) - Company Total Cash Volume|ORMP: Company Cash on Hand|ENTX (Entera Bio Ltd) - Company Cash and Cash Equivalents|HYFT: Company Cash Volume|Company Cash on Hand ABVC BioPharma Inc.|CPIX (cumberlandpharma.com) - Company Cash Volume|Company Cash Funds QNTM|Company Cash Volume FGEN|Company Cash on Hand Telomir Pharmaceuticals TELO|Company Cash Volume RANI (ranitherapeutics.com)|SNYR (Synergy CHC Corporation) - Company Total Cash Volume|LEXX: Company Cash on Hand|Company Cash Balance PULM (Pulmatrix Corporation)|Pheton Holdings Limited (PTHL) - Company Cash Funds|Company Cash on Hand Aptorum|Company Cash on Hand LYRA|Impact BioMedical Inc - Company Total Cash Volume|Company Cash Volume TNFA|YCBD - Company Cash Reserve|PainReform Ltd. - Company Cash on Hand|CYTO (Auris Medical) - Company Total Cash Volume|LIPO - Company Cash Funds|Company Cash Balance OPTN (OptiNose)|PIRS: Company Cash Volume|Procaps Group S.A. (PROC) - Company Cash Volume|PTPI (Petros Pharma) - Company Cash Volume|QLI: Company Cash Balance|Company Cash Volume SLRN|TFFP (TFF Pharmaceuticals Inc.) - Company Cash Balance